Anakinra Liquid
NDC Package 68594-050-99

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Anakinra liquids is a medication used alone or with other medications to treat rheumatoid arthritis. This formulation utilizes a liquid delivery system. Marketed by Boehringer Ingelheim Rcv Gmbh & Co Kg, this product is identified by NDC 68594-050.

Identification & Billing

NDC Package Code
68594-050-99
Package Description
20 mg in 1 BOTTLE
Product Code
68594-050
11-Digit Billing Format
68594005099

Clinical Specifications

Proprietary Name
Anakinra
Non-Proprietary Name
Anakinra
Substance Name
Anakinra
Dosage Form
Liquid - A dosage form consisting of a pure chemical in its liquid1 state. This dosage form term should not be applied to solutions.
Active Ingredient(s)
ANAKINRA 220 mg/220mg
Usage Information
This medication is used alone or with other medications to treat rheumatoid arthritis. It helps to slow joint damage and reduces the joint pain/swelling caused by rheumatoid arthritis so that you can move better. Anakinra is a man-made form of a natural protein (interleukin-1 receptor antagonist) made by the body. It helps to block the effects of another protein (interleukin-1) which can cause joint pain/swelling/stiffness. Anakinra is also used to treat a certain condition called Neonatal-Onset Multisystem Inflammatory Disease (NOMID). It helps to improve symptoms of the disease such as fever, rash, joint pain, vomiting, and headache.

Regulatory & Marketing

Labeler Name
Boehringer Ingelheim Rcv Gmbh & Co Kg
Product Type
Bulk Ingredient
Marketing Category
BULK INGREDIENT - A category specifying that a product is marketed as a bulk ingredient.
Start Marketing Date
11-14-2001
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68594-050-99 identifies a specific commercial package of 20 mg in 1 bottle of Anakinra (UNFINISHED drug), a bulk ingredient labeled by Boehringer Ingelheim Rcv Gmbh & Co Kg. This liquid is formulated for use and contains anakinra as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Boehringer Ingelheim Rcv Gmbh & Co Kg on November 14, 2001. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used alone or with other medications to treat rheumatoid arthritis. It helps to slow joint damage and reduces the joint pain/swelling caused by rheumatoid arthritis so that you can move better. Anakinra is a man-made form of a natural protein (interleukin-1 receptor antagonist) made by the body. It helps to block the effects of another protein (interleukin-1) which can cause joint pain/swelling/stiffness. Anakinra is also used to treat a certain condition called Neonatal-Onset Multisystem Inflammatory Disease (NOMID). It helps to improve symptoms of the disease such as fever, rash, joint pain, vomiting, and headache.

How is this Boehringer Ingelheim Rcv Gmbh & Co Kg product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68594005099. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68594-050-99
11-Digit CMS (5-4-2)
68594-0050-99

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.